{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T17:48:20Z","timestamp":1765734500102,"version":"3.48.0"},"reference-count":57,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"unspecified","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005205","name":"Janssen Research & Development","doi-asserted-by":"crossref","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100005205","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,6,26]]},"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Head-to-head clinical trials are common in psoriasis, but scarce in psoriatic arthritis (PsA), making treatment comparisons between therapeutic classes difficult. This study describes the relative effectiveness of targeted synthetic (ts) and biologic (b) disease-modifying antirheumatic drugs (DMARDs) on patient-reported outcomes (PROs) through network meta-analysis (NMA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>A systematic literature review (SLR) was conducted in January 2020. Bayesian NMAs were conducted to compare treatments on Health Assessment Questionnaire Disability Index (HAQ-DI) and 36-item Short Form (SF-36) Health Survey including Mental Component Summary (MCS) and Physical Component Summary (PCS) scores.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data sources<\/jats:title>\n                    <jats:p>Ovid MEDLINE (including Epub Ahead of Print, In-Process &amp; Other Non-Indexed Citations and Daily),Embase and Cochrane Central Register of Controlled Trials.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Eligibility criteria<\/jats:title>\n                    <jats:p>Phase III randomised controlled trials (RCTs) evaluating patients with PsA receiving tsDMARDS, bDMARDs or placebo were included in the SLR; there was no restriction on outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data extraction and synthesis<\/jats:title>\n                    <jats:p>Two independent researchers reviewed all citations. Data for studies meeting all inclusion criteria were extracted into a standardised Excel-based form by one reviewer and validated by a second reviewer. A third reviewer was consulted to resolve any discrepancies, as necessary. Risk of bias was assessed using the The National Institute for Health and Care Excellence clinical effectiveness quality assessment checklist.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 26 RCTs were included. For HAQ-DI, SF-36 PCS and SF-36 MCS scores, intravenous tumour necrosis factor (TNF) alpha inhibitors generally ranked higher than most other classes of therapies available to treat patients with PsA. For almost all outcomes, several interleukin (IL)-23, IL-17A, subcutaneous TNF and IL-12\/23 agents offered comparable improvement, while cytotoxic T-lymphocyte-associated antigen 4, phosphodiesterase-4 and Janus kinase inhibitors often had the lowest efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>While intravenous TNFs may provide some improvements in PROs relative to several other tsDMARDs and bDMARDs for the treatment of patients with PsA, differences between classes of therapies across outcomes were small.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-062306","type":"journal-article","created":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T11:50:59Z","timestamp":1699444259000},"page":"e062306","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":5,"title":["Systematic literature review and network meta-analysis of therapies for psoriatic arthritis on patient-reported outcomes"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2571-788X","authenticated-orcid":false,"given":"Peter","family":"Nash","sequence":"first","affiliation":[{"name":"School of Medicine, Griffith University, Brisbane, Queensland, Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan P","family":"Dutz","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Skin Sciences, The University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steve","family":"Peterson","sequence":"additional","affiliation":[{"name":"Immunology Global Commercial Strategy Organization, Janssen Global Services LLC, Horsham, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barkha P","family":"Patel","sequence":"additional","affiliation":[{"name":"EVERSANA, Burlington, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiefer","family":"Eaton","sequence":"additional","affiliation":[{"name":"EVERSANA, Burlington, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"May","family":"Shawi","sequence":"additional","affiliation":[{"name":"Immunology Medical Affairs, Janssen Global Services LLC, Horsham, Pennsylvania, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Zazzetti","sequence":"additional","affiliation":[{"name":"Immunology Medical Affairs, Janssen Latin America, LLC, Buenos Aires, Argentina"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1235-0679","authenticated-orcid":false,"given":"James Cheng-Chung","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Allergy Immunology & Rheumatology, Chung Shan Medical University Hospital, Taichung, Taiwan"},{"name":"Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan"},{"name":"Graduate Institute of Integrated Medicine, China Medical University, Taichung, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,11,8]]},"reference":[{"key":"2025121409444107000_13.11.e062306.1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.171406"},{"key":"2025121409444107000_13.11.e062306.2","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.rdc.2016.01.002","article-title":"Patient-reported outcomes in psoriatic arthritis","volume":"42","author":"Orbai","year":"2016","journal-title":"Rheum Dis Clin North Am"},{"key":"2025121409444107000_13.11.e062306.3","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/S0140-6736(20)30564-X","article-title":"Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3B trial","volume":"395","author":"McInnes","year":"2020","journal-title":"The Lancet"},{"key":"2025121409444107000_13.11.e062306.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215386"},{"key":"2025121409444107000_13.11.e062306.5","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-014-2994-2"},{"key":"2025121409444107000_13.11.e062306.6","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab119"},{"key":"2025121409444107000_13.11.e062306.7","doi-asserted-by":"crossref","DOI":"10.1186\/1477-7525-7-25","article-title":"The health-related quality of life in rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis: a comparison with a selected sample of healthy people","volume":"7","author":"Salaffi","year":"2009","journal-title":"Health Qual Life Outcomes"},{"key":"2025121409444107000_13.11.e062306.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213286"},{"key":"2025121409444107000_13.11.e062306.9","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780230202"},{"key":"2025121409444107000_13.11.e062306.10","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.190122"},{"key":"2025121409444107000_13.11.e062306.11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"2025121409444107000_13.11.e062306.12","doi-asserted-by":"publisher","DOI":"10.7326\/M14-2385"},{"key":"2025121409444107000_13.11.e062306.13","unstructured":"National Institute For Health And Care Excellence . Single technology appraisal: user guide for company evidence submission template, . 2017 Available: https:\/\/www.nice.org.uk\/process\/pmg24\/chapter\/clinical-effectiveness#quality-assessment-of-the-relevant-clinical-effectiveness-evidence [Accessed 5 May 2021]."},{"key":"2025121409444107000_13.11.e062306.14","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12458724"},{"key":"2025121409444107000_13.11.e062306.15","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X13485157"},{"key":"2025121409444107000_13.11.e062306.16","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12455847"},{"key":"2025121409444107000_13.11.e062306.17","first-page":"81","article-title":"Guselkumab for the treatment of moderate-to-severe plaque psoriasis during induction phase: a systematic review and network meta-analysis","volume":"4","author":"Cameron","year":"2019","journal-title":"JPPA"},{"key":"2025121409444107000_13.11.e062306.18","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40744-018-0106-6","article-title":"Secukinumab versus adalimumab for psoriatic arthritis: comparative effectiveness up to 48 weeks using a matching-adjusted indirect comparison","volume":"5","author":"Nash","year":"2018","journal-title":"Rheumatol Ther"},{"key":"2025121409444107000_13.11.e062306.19","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2217\/cer-2018-0075","article-title":"Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed Biologics\/Apremilast: a network meta-analysis","volume":"7","author":"McInnes","year":"2018","journal-title":"J Comp Eff Res"},{"key":"2025121409444107000_13.11.e062306.20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)61134-5"},{"key":"2025121409444107000_13.11.e062306.21","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-018-1551-x","article-title":"Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial","volume":"20","author":"Nash","year":"2018","journal-title":"Arthritis Res Ther"},{"key":"2025121409444107000_13.11.e062306.22","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s40744-019-0163-5","article-title":"Efficacy and safety of subcutaneous Secukinumab 150 mg with or without loading regimen in Psoriatic arthritis: results from the FUTURE 4 study","volume":"6","author":"Kivitz","year":"2019","journal-title":"Rheumatol Ther"},{"key":"2025121409444107000_13.11.e062306.23","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212687"},{"key":"2025121409444107000_13.11.e062306.24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31429-0"},{"key":"2025121409444107000_13.11.e062306.25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615977"},{"key":"2025121409444107000_13.11.e062306.26","doi-asserted-by":"crossref","first-page":"100601","DOI":"10.1016\/j.curtheres.2020.100601","article-title":"Network meta-analysis of tofacitinib, biologic disease-modifying antirheumatic drugs, and apremilast for the treatment of psoriatic arthritis","volume":"93","author":"Gladman","year":"2020","journal-title":"Current Therapeutic Research"},{"key":"2025121409444107000_13.11.e062306.27","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2474-15-26","article-title":"Systematic review, network meta-analysis and economic evaluation of biological therapy for the management of active Psoriatic arthritis","volume":"15","author":"Cawson","year":"2014","journal-title":"BMC Musculoskelet Disord"},{"key":"2025121409444107000_13.11.e062306.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2020.04.009"},{"key":"2025121409444107000_13.11.e062306.29","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1007\/s11606-019-04976-x","article-title":"How often do systematic reviews exclude articles not published in English","volume":"34","author":"Jackson","year":"2019","journal-title":"J Gen Intern Med"},{"key":"2025121409444107000_13.11.e062306.30","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s41927-020-00130-x","article-title":"The pharmacological and clinical aspects behind dose loading of biological disease modifying anti-rheumatic drugs (bDMARDs) in auto-immune rheumatic diseases (AIRDS): rationale and systematic narrative review of clinical evidence","volume":"4","author":"Geurts-Voerman","year":"2020","journal-title":"BMC Rheumatol"},{"key":"2025121409444107000_13.11.e062306.31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30265-8"},{"key":"2025121409444107000_13.11.e062306.32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30263-4"},{"key":"2025121409444107000_13.11.e062306.33","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key161"},{"key":"2025121409444107000_13.11.e062306.34","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209709"},{"key":"2025121409444107000_13.11.e062306.35","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60594-2"},{"key":"2025121409444107000_13.11.e062306.36","unstructured":"Centre for reviews and dissemination\/centre for health economics technology assessment group; 2017. Multiple technology appraisal: Certolizumab Pegol and Secukinumab for treating active Psoriatic arthritis following inadequate response to disease modifying anti-rheumatic Drugs[Id579 ]committee papers"},{"key":"2025121409444107000_13.11.e062306.37","unstructured":"Janssen Research & Development . A phase 3 multicenter, randomized, double-blind, placebo-controlled trial of Ustekinumab, a fully human anti-IL-12\/23P40 Monoclonal antibody. In: Administered Subcutaneously, in Subjects with Active Psoriatic Arthritis - PSUMMIT I."},{"key":"2025121409444107000_13.11.e062306.38","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204655"},{"key":"2025121409444107000_13.11.e062306.39","unstructured":"Janssen Research & Development . A phase 3 multicenter, randomized, double-blind, placebo-controlled trial of ustekinumab, a fully human anti-IL-12\/23P40 monoclonal antibody, administered subcutaneously. In: Subjects With Active Psoriatic Arthritis Including Those Previously Treated With Biologic Anti-TNF Agent(s) - PSUMMIT II. (accessed 5 May 2021). 2013."},{"key":"2025121409444107000_13.11.e062306.40","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1002\/acr.22044","article-title":"Patient-reported outcomes and the association with clinical response in patients with active Psoriatic arthritis treated with Golimumab: findings through 2 years of a phase III, multicenter, randomized, double-blind, placebo-controlled trial","volume":"65","author":"Kavanaugh","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025121409444107000_13.11.e062306.41","first-page":"1040","article-title":"Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy","volume":"34","author":"Genovese","year":"2007","journal-title":"J Rheumatol"},{"key":"2025121409444107000_13.11.e062306.42","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/acr.22256","article-title":"Effect of certolizumab Pegol on multiple facets of psoriatic arthritis as reported by patients: 24-week patient-reported outcome results of a phase III, multicenter study","volume":"66","author":"Gladman","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025121409444107000_13.11.e062306.43","doi-asserted-by":"publisher","DOI":"10.1002\/art.21306"},{"key":"2025121409444107000_13.11.e062306.44","doi-asserted-by":"publisher","DOI":"10.1002\/art.20335"},{"key":"2025121409444107000_13.11.e062306.45","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.091093"},{"key":"2025121409444107000_13.11.e062306.46","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/art.40226","article-title":"Safety and efficacy of intravenous Golimumab in patients with active Psoriatic arthritis: results through week twenty-four of the go-vibrant study","volume":"69","author":"Kavanaugh","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2025121409444107000_13.11.e062306.47","unstructured":"Antoni C . CSR C0168T50 clinical study report: a multicenter, randomized, double-blind trial of anti-TNF\u03b1 chimeric monoclonal antibody (Infliximab) for the treatment of subjects with psoriatic arthritis - IMPACT 2. 2004."},{"key":"2025121409444107000_13.11.e062306.48","first-page":"1150","article-title":"Infliximab improves signs and symptoms of Psoriatic arthritis: results of the IMPACT 2 trial","volume":"64","author":"Antoni","year":"2005","journal-title":"ARD"},{"key":"2025121409444107000_13.11.e062306.49","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000808","article-title":"Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL beyond","volume":"5","author":"Strand","year":"2019","journal-title":"RMD Open"},{"key":"2025121409444107000_13.11.e062306.50","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1615975"},{"key":"2025121409444107000_13.11.e062306.51","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000806","article-title":"Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs","volume":"5","author":"Strand","year":"2019","journal-title":"RMD Open"},{"key":"2025121409444107000_13.11.e062306.52","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205056"},{"key":"2025121409444107000_13.11.e062306.53","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.151376"},{"key":"2025121409444107000_13.11.e062306.54","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207963"},{"key":"2025121409444107000_13.11.e062306.55","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/rheumatology\/key032","article-title":"Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized","volume":"57","author":"Wells","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2025121409444107000_13.11.e062306.56","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211568"},{"key":"2025121409444107000_13.11.e062306.57","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-210724"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-062306","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T17:44:51Z","timestamp":1765734291000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-062306"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":57,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2023,11,8]]},"published-print":{"date-parts":[[2023,11]]}},"alternative-id":["10.1136\/bmjopen-2022-062306"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-062306","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2023,11]]}}}